We have entered into a capital and business alliance with PST Corporation, which has strengths in voice biomarker technology.

management

Products/Business

Alliance

We have entered into a capital and business alliance with PST Corporation, a company specializing in voice biomarker technology. This alliance aims to analyze mental and physical health from voice data, promoting health and early detection of disease symptoms.

February 19, 2025

ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Masafumi Sugimoto) is pleased to announce that it has entered into an investment agreement with PST Corporation (Headquarters: Naka-ku, Yokohama City, Representative Director: Hiroshi Otsuka, hereinafter referred to as PST), a company with strengths in voice biomarker technology, effective February 13th.

Background and purpose of the business alliance

Our purpose is to energize the world by delivering "health" to people around the globe through our products and services, thereby leading all individuals and society around us to well-being. Based on health, which is the core value of our business, we have continued to challenge ourselves in new areas in response to social issues and changes in our customers.

Voice contains a wealth of information that reflects people's physical and psychological states. PST Corporation has been working to analyze this valuable information, creating and patenting numerous intellectual properties, and has developed "voice biomarker technology." Utilizing this technology, PST is developing various products and services, initially focusing on the social issue of mental health, as a way to easily grasp people's physical and mental health status, enabling them to live healthy daily lives.

In modern society, it is difficult to recognize stress and mental health problems, making the early detection, early intervention, and countermeasures for depression and other mental illnesses urgent issues. Furthermore, since the COVID-19 pandemic, interest in mental health has increased, and effective and continuous mental health management is considered important.

Against this backdrop, we invested in PST Corporation to support individuals in understanding their physical and mental health and taking appropriate action early on. Aiming to realize a well-being society, we will address important issues in modern society and develop innovative health solutions in conjunction with our existing businesses.

Features of PST's voice biomarker technology

The company's developed "voice biomarker technology" analyzes nonverbal information before it is spoken, enabling the detection of subtle changes in physical and mental health and emotions that were difficult to capture with conventional methods. Furthermore, it continues to improve daily through the accumulation of a wealth of knowledge and data, and evidence and intellectual property are also being built up. The greatest advantage of this technology is that it allows for objective checks of physical and mental health and changes in a non-invasive and simple manner. Because it can grasp the state of mind and body from everyday conversation, continuous monitoring is possible without burdening the user. This enables the early detection of physical and mental changes, more effective health management, and the provision of data-driven, personalized health solutions. Moreover, as mentioned above, because it analyzes nonverbal information, it can also be deployed globally.

Future outlook

The impact of this matter on our consolidated financial results for the fiscal year ending March 2025 is expected to be minor, and we will promptly inform you of any further matters that need to be disclosed.

About PST Corporation

Company Name PST Corporation
location 905, Industrial Trade Center, 2 Yamashita-cho, Naka-ku, Yokohama City
representative Hiroshi Otsuka
Business details
Research and development of vocal biomarker technology based on voice pathology analysis technology; research and development and sales of the healthcare voice analysis platform "VOISLOG® (*)"; research and development and sales of software as a medical device (SaMD) using vocal biomarker technology for the medical field, subject to approval (affiliated company: PST Medical Co., Ltd.); home nursing care business (affiliated company: UIX Co., Ltd.); research and development and sales of recovery solution-related products, etc.
*VOISLOG is a registered trademark of PST Corporation.
Home page https://www.medical-pst.com/